After completing combined M.D., Ph.D. training at Tufts University, Gary D. Hammer, M.D., Ph.D. completed his residency in Internal Medicine, fellowship in Endocrinology and a post-doctoral fellowship at University of California-San Francisco. Dr. Hammer joined the faculty at University of Michigan in 1999 as an Assistant Professor, was promoted to Associate Professor in 2005, and became a full Professor in 2011. Dr. Hammer currently serves as the Director of the Endocrine Oncology Program in the Comprehensive Cancer Center at UM where he holds the Millie Schembechler Professorship in Adrenal Cancer. The Program is considered a worldwide leader in endocrine cancers - exemplified by its recent leadership role in 3 recent platforms of the NCI TCGA (papillary thyroid cancer, adrenocortical carcinoma and pheochromocytoma). Specifically, the Program is uniquely recognized an international center of excellence for research and treatment of adrenal cancer. Dr. Hammer is best recognized for his research in adrenal homeostasis and neoplasia and for the treatment of adrenal cancer. He has received the UM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research in Endocrinology and is a member of American Society for Clinical Investigation and Association of American Physicians. He is the editor of three textbooks: Adrenocortical Carcinoma: Basic Science and Clinical Concepts (Springer 2011), Pathophysiology of Disease: An Introduction to Clinical Medicine (Harper Row, 2018) and Genetics of Steroid Disorders (Elsevier, 2014). He has served in numerous capacities across the tripartite constituencies of the Endocrine Society including Overall Chair of the 2017 Annual Meeting, Chair of the Student Affairs Committee, Chair of the Mentoring Task Force, Basic Science Chair of Trainee Day at Annual Meeting, Council Member at Large and a Society Ambassador to King Edward Memorial Hospital in Mumbai India as part of inaugural Endocrine Society Ambassador Exchange Program. Hammer's own laboratory has focused on 1) defining stem/progenitor cells and critical signaling/transcriptional programs that dictate cell fate, self-renewal, multipotency in health and disease; 2) directing landmark genetic/genomic studies in adrenal neoplasia/cancer; and 3) leveraging critical cellular pathways to launch ongoing international clinical adrenal trials with newly-developed targeted therapeutics. Most recently, Dr. Hammer cofounded Millendo Therapeutics focusing on therapies for adrenal cancer and related endocrine diseases of steroid excess. With UofM colleagues he also has formed the American Australian ASIAN ALLIANCE (A5) that aims to facilitate and leverage international collaboration for adrenal disease.